IMV, part of the Science and Medicine Group and the leading market research and business intelligence provider to the ...

IMV’s Survivin-Targeted T Cell Therapy Shows Durable Clinical Benefits in Phase 2 Study in Patients with Hard-to-Treat Advanced Recurrent Ovarian Cancer 37% (7/19) patients experienced clinical ...

Canada's IMV is a small but high-profile biotechnology company engaged in the development of a COVID-19 vaccine. Investors are awaiting the publication of the clinical Phase 1 results. Amid daily ...

IMV Inc. (IMV) Q4 2022 Earnings Conference Call March 16, 2023 8:00 AM ETCompany ParticipantsAndrew Hall - Chief Executive OfficerBrittany Davison - Chief ...

IMV to host a conference call and webcast today, February 25, 2020 at 8:00 a.m. EST; data also to be featured at KOL symposium on Thursday, February 27, 2020 February 25, 2020 03:05 AM Eastern ...

ImmunoVaccine Inc.(IMV: CA) has updated data on its investigator-sponsored phase 1 clinical trial testing the safety and immunogenicity of its DepoVax-based, small B-cell epitope peptide vaccine ...

IMV will share preliminary data from the open-label phase 2b studies when enrollment of stage 1 is complete. The other milestone on the horizon is a release of preliminary phase 1 results in the ...

A Phase 1 clinical trial in bladder cancer will open early 2022. For more information, visit www.imv-inc.com and connect with us on Twitter and LinkedIn. IMV Forward-Looking Statements ...

Compared with the general population, patients receiving IMV who had a history of cirrhosis had a significantly increased adjusted odds ratio (OR) for mortality (OR 1.51; P <.001; 95% CI, 1.45-1. ...

IMV INC (IMV) delivered earnings and revenue surprises of -27.27% and 27.50%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?